Journal ArticleDOI
Targeting public neoantigens for cancer immunotherapy.
Alexander H. Pearlman,Alexander H. Pearlman,Michael S. Hwang,Maximilian F. Konig,Emily Han-Chung Hsiue,Emily Han-Chung Hsiue,Jacqueline Douglass,Jacqueline Douglass,Sarah R. DiNapoli,Sarah R. DiNapoli,Brian J. Mog,Chetan Bettegowda,Drew M. Pardoll,Sandra B. Gabelli,Nicholas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +17 more
- Vol. 2, Iss: 5, pp 487-497
TLDR
The opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them are reviewed.Abstract:
Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic agents can also be developed against public neoantigens derived from recurrent mutations in cancer driver genes. The latter approaches target proteins that are indispensable for tumor growth, and each therapeutic agent can be applied to numerous patients. Here we review the opportunities and challenges involved in the identification of suitable public neoantigen targets and the development of therapeutic agents targeting them. Zhou and colleagues discuss the opportunities and challenges in targeting public neoantigens for cancer immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich,Quinlen F. Marshall,John M. Warrington,Rasika Premaratne,Alvin Farrel,David Groff,Wei Li,Moreno Di Marco,Erin Runbeck,Hau Truong,Jugmohit S. Toor,Sarvind Tripathi,Son Nguyen,Helena Shen,Tiffany Noel,Nicole L. Church,Amber K. Weiner,Nathan M. Kendsersky,Daniel Martinez,Rebecca Weisberg,Molly Christie,Laurence C. Eisenlohr,Kristopher R. Bosse,Kristopher R. Bosse,Dimiter S. Dimitrov,Stefan Stevanovic,Nikolaos G. Sgourakis,Ben R. Kiefel,John M. Maris,John M. Maris +29 more
TL;DR: In this article, a peptide-centric chimeric antigen receptor (CAR) was proposed to target unmutated peptide QYNPIRTTF, discovered on HLA-A*24:02, derived from the neuroblastoma dependency gene and master transcriptional regulator PHOX2B.
Journal ArticleDOI
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
TL;DR: The differing mechanisms of T cell antigen recognition and signal transduction mediated through CARs and TCRs are described and both classical and emerging pre-clinical strategies for antigen-specific TCR discovery, enhancement, and validation are discussed.
Journal ArticleDOI
Neoantigens: promising targets for cancer therapy
TL;DR: Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames as mentioned in this paper .
Journal ArticleDOI
Thermal immuno-nanomedicine in cancer
Zhe Yang,Di Gao,Jing Zhao,Gaojie Yang,Mingli Guo,Yiming Wang,Xuechun Ren,Jong Seung Kim,L. Jin,Zhongmin Tian,Jing Zhang +10 more
Journal ArticleDOI
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
TL;DR: In this review, Bewersdorf and Abdel-Wahab discuss the development of promising new molecular targeted approaches for AML, including menin inhibition, novel IDH1/2 inhibitors, and preclinical means to target TET2, ASXL1, and RNA splicing factor mutations.
References
More filters
Journal ArticleDOI
A ras-Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion
Boris Linard,Stéphane Bézieau,Houssem Benlalam,Nathalie Labarrière,Yannick Guilloux,Elisabeth Diez,Francine Jotereau +6 more
TL;DR: Data show that oncogenic protein mutations can create shared tumor-specific CTL epitopes, efficiently presented by tumor cells, and that screening for oncogene-transfected COS cell recognition by TIL (from tumors containing mutations) is a powerful approach for the identification of these epitopes.
Journal ArticleDOI
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes
Alena Gros,Eric Tran,Maria R. Parkhurst,Sadia Ilyas,Anna Pasetto,Eric M. Groh,Paul F. Robbins,Rami Yossef,Andrea Garcia-Garijo,Carlos Alberto Fajardo,Todd D. Prickett,Li Jia,Jared J. Gartner,Satyajit Ray,Lien Ngo,John R. Wunderllich,James Chih-Hsin Yang,Steven A. Rosenberg +17 more
TL;DR: The existence of circulating T cells targeting neoantigens in GI cancer patients is demonstrated and an approach to generate enriched populations of personalized neoantigen-specific lymphocytes and isolate TCRs that could be exploited therapeutically to treat cancer is provided.
Journal ArticleDOI
Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma
Joshua R. Veatch,Sylvia Lee,Matthew Fitzgibbon,I-Ting Chow,Brenda Jesernig,Thomas M. Schmitt,Ying Ying Kong,Julia Kargl,Julia Kargl,A. McGarry Houghton,John A. Thompson,Martin W. McIntosh,William W. Kwok,Stanley R. Riddell +13 more
TL;DR: In this article, the authors describe a stage IV acral melanoma patient who achieved a complete response following adoptive transfer of tumor-infiltrating lymphocytes (TILs).
Journal ArticleDOI
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities
Kole T. Roybal,Wendell A. Lim +1 more
TL;DR: The current state of engineered immune cell therapeutics and their unique capabilities compared to small molecules and biologics are reviewed and a long-term vision for the use of synthetic biology to engineer immune cells as a general sensor-response platform to precisely detect disease, to remodel disease microenvironments, and to treat a potentially wide range of challenging diseases is given.
Journal ArticleDOI
Neoantigen quality, not quantity
TL;DR: Prioritizing expressed clonal neoantigens in genes required for cancer cell survival may reduce the likelihood of resistance to neoantigen therapies.